241 related articles for article (PubMed ID: 38409030)
21. Comparison of PARPis with Angiogenesis Inhibitors and Chemotherapy for Maintenance in Ovarian Cancer: A Network Meta-Analysis.
Feng Y; Huang H; Wan T; Zhang C; Tong C; Liu J
Adv Ther; 2019 Dec; 36(12):3368-3380. PubMed ID: 31599396
[TBL] [Abstract][Full Text] [Related]
22. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
Swisher EM; Lin KK; Oza AM; Scott CL; Giordano H; Sun J; Konecny GE; Coleman RL; Tinker AV; O'Malley DM; Kristeleit RS; Ma L; Bell-McGuinn KM; Brenton JD; Cragun JM; Oaknin A; Ray-Coquard I; Harrell MI; Mann E; Kaufmann SH; Floquet A; Leary A; Harding TC; Goble S; Maloney L; Isaacson J; Allen AR; Rolfe L; Yelensky R; Raponi M; McNeish IA
Lancet Oncol; 2017 Jan; 18(1):75-87. PubMed ID: 27908594
[TBL] [Abstract][Full Text] [Related]
23. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
Wiggans AJ; Cass GK; Bryant A; Lawrie TA; Morrison J
Cochrane Database Syst Rev; 2015 May; 2015(5):CD007929. PubMed ID: 25991068
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial.
Frenel JS; Kim JW; Aryal N; Asher R; Berton D; Vidal L; Pautier P; Ledermann JA; Penson RT; Oza AM; Korach J; Huzarski T; Pignata S; Colombo N; Park-Simon TW; Tamura K; Sonke GS; Freimund AE; Lee CK; Pujade-Lauraine E
Ann Oncol; 2022 Oct; 33(10):1021-1028. PubMed ID: 35772665
[TBL] [Abstract][Full Text] [Related]
25. Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial.
Pujade-Lauraine E; Selle F; Scambia G; Asselain B; Marmé F; Lindemann K; Colombo N; Mądry R; Glasspool R; Vergote I; Korach J; Lheureux S; Dubot C; Oaknin A; Zamagni C; Heitz F; Gladieff L; Rubio-Pérez MJ; Scollo P; Blakeley C; Shaw B; Ray-Coquard I; Redondo A;
Ann Oncol; 2023 Dec; 34(12):1152-1164. PubMed ID: 37797734
[TBL] [Abstract][Full Text] [Related]
26. Cytoreductive surgery for advanced epithelial ovarian cancer in the poly(ADP-ribose) polymerase inhibitors era-Is it time for a new paradigm shift? A systematic review and meta-analysis.
Peters ITA; Marchetti C; De Palma A; Giannarelli D; Carcagnì A; Scambia G; Fagotti A
Eur J Cancer; 2023 Jul; 187():77-86. PubMed ID: 37130463
[TBL] [Abstract][Full Text] [Related]
27. Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status.
Tomao F; Bardhi E; Di Pinto A; Sassu CM; Biagioli E; Petrella MC; Palaia I; Muzii L; Colombo N; Panici PB
Cancer Treat Rev; 2019 Nov; 80():101909. PubMed ID: 31629204
[TBL] [Abstract][Full Text] [Related]
28. DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment.
McMullen M; Karakasis K; Loembe B; Dean E; Parr G; Oza AM
Int J Gynecol Cancer; 2020 Nov; 30(11):1824-1828. PubMed ID: 32878963
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of PARP inhibitors in the treatment of advanced ovarian cancer: An updated systematic review and meta-analysis of randomized controlled trials.
Hao J; Liu Y; Zhang T; He J; Zhao H; An R; Xue Y
Crit Rev Oncol Hematol; 2021 Jan; 157():103145. PubMed ID: 33254040
[TBL] [Abstract][Full Text] [Related]
30. Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.
Alvarez Secord A; O'Malley DM; Sood AK; Westin SN; Liu JF
Gynecol Oncol; 2021 Aug; 162(2):482-495. PubMed ID: 34090705
[TBL] [Abstract][Full Text] [Related]
31. Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis.
Bartoletti M; Pelizzari G; Gerratana L; Bortot L; Lombardi D; Nicoloso M; Scalone S; Giorda G; Baldassarre G; Sorio R; Puglisi F
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32471250
[TBL] [Abstract][Full Text] [Related]
32. Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma.
Oza AM; Lorusso D; Aghajanian C; Oaknin A; Dean A; Colombo N; Weberpals JI; Clamp AR; Scambia G; Leary A; Holloway RW; Gancedo MA; Fong PC; Goh JC; O'Malley DM; Armstrong DK; Banerjee S; García-Donas J; Swisher EM; Cella D; Meunier J; Goble S; Cameron T; Maloney L; Mörk AC; Bedel J; Ledermann JA; Coleman RL
J Clin Oncol; 2020 Oct; 38(30):3494-3505. PubMed ID: 32840418
[TBL] [Abstract][Full Text] [Related]
33. Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events.
Madariaga A; Bowering V; Ahrari S; Oza AM; Lheureux S
Int J Gynecol Cancer; 2020 Jul; 30(7):903-915. PubMed ID: 32276934
[TBL] [Abstract][Full Text] [Related]
34. PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival.
Shao F; Duan Y; Zhao Y; Li Y; Liu J; Zhang C; He S
Aging (Albany NY); 2021 Mar; 13(6):8975-8988. PubMed ID: 33705352
[TBL] [Abstract][Full Text] [Related]
35. The impact of PARP inhibitors in the whole scenario of ovarian cancer management: A systematic review and network meta-analysis.
Staropoli N; Ciliberto D; Luciano F; Napoli C; Costa M; Rossini G; Arbitrio M; Labanca C; Riillo C; Del Giudice T; Crispino A; Salvino A; Galvano A; Russo A; Tassone P; Tagliaferri P
Crit Rev Oncol Hematol; 2024 Jan; 193():104229. PubMed ID: 38065404
[TBL] [Abstract][Full Text] [Related]
36. Frontline PARP inhibitor maintenance therapy in ovarian cancer: A Society of Gynecologic Oncology practice statement.
Pothuri B; O'Cearbhaill R; Eskander R; Armstrong D
Gynecol Oncol; 2020 Oct; 159(1):8-12. PubMed ID: 32778410
[TBL] [Abstract][Full Text] [Related]
37. The Era of PARP inhibitors in ovarian cancer: "Class Action" or not? A systematic review and meta-analysis.
Staropoli N; Ciliberto D; Del Giudice T; Iuliano E; Cucè M; Grillone F; Salvino A; Barbieri V; Russo A; Tassone P; Tagliaferri P
Crit Rev Oncol Hematol; 2018 Nov; 131():83-89. PubMed ID: 30293710
[TBL] [Abstract][Full Text] [Related]
38. PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectations.
Vanacker H; Harter P; Labidi-Galy SI; Banerjee S; Oaknin A; Lorusso D; Ray-Coquard I
Cancer Treat Rev; 2021 Sep; 99():102255. PubMed ID: 34332292
[TBL] [Abstract][Full Text] [Related]
39. PARP Inhibitors in Ovarian Cancer: A Review.
O'Malley DM; Krivak TC; Kabil N; Munley J; Moore KN
Target Oncol; 2023 Jul; 18(4):471-503. PubMed ID: 37268756
[TBL] [Abstract][Full Text] [Related]
40. PARP inhibitors: risk factors for toxicity and matching patients to the proper poly (ADP-ribose) polymerase inhibitor (PARPi) therapy.
Chelariu-Raicu A; Trillsch F; Burges A; Czogalla B; Hester A; Wuerstlein R; Harbeck N; Mahner S
Int J Gynecol Cancer; 2023 May; 33(5):812-822. PubMed ID: 36707086
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
